

MANAGEMENT

GEORGE P. VLASUK, PHD
President and Chief Executive Officer

RICK LUNDBERG
Vice President of Business, Operations,
and Finance

EDDINE SAIAH, PHD
Vice President of Drug Discovery

BOARD OF DIRECTORS

ALAN CRANE
(CO-FOUNDER & CHAIRMAN OF THE BOARD)
Polaris Partners

JEAN-FRANÇOIS FORMELA, MD
Atlas Venture

PAUL FRIEDMAN, MD
(INDEPENDENT DIRECTOR)
Former President & CEO
Incyte Corporation

BRIAN GALLAGHER, PhD
SR One

MARIAN NAKADA, PhD
Johnson & Johnson Innovation –JJDC

GEORGE P. VLASUK, PHD
Navitor

SCIENTIFIC ADVISORY BOARD

DAVID SABATINI, MD, PhD
*(CO-FOUNDER & CHAIRMAN OF THE
SCIENTIFIC ADVISORY BOARD)*
Massachusetts Institute of Technology,
Whitehead Institute, HHMI Investigator

BRIAN HUBBARD, PhD
The Broad Institute

THOMAS HUGHES, PhD
Zafgen

BRENDAN MANNING, PhD
Harvard School of Public Health

MARK MURCKO, PhD
Principal, Disruptive Biomedical, LLC

BLAKE RASMUSSEN, PhD
University of Texas Medical Branch
(UTMB)

JIM TOBIN, PhD
Johnson & Johnson Innovation LLC

NAVITOR THERAPEUTICS

1030 Massachusetts Avenue
Suite 410
Cambridge, MA 02138
(857) 285-4300
info@navitorpharma.com


Navitor is pioneering the selective targeting of mTORC1 activation to develop a new class of medicines for age-related diseases to improve human health.

An unprecedented and powerful therapeutic approach to address unmet needs in age-related diseases and certain rare disorders.

With increasing life expectancy, the need to address chronic diseases that affect long-term health in aging populations is expanding. Navitor’s drug discovery platform leverages proprietary intellectual property and know-how related to key targets within the cellular pathways required for the activation of mTORC1 as well as their fundamental role in age-related disease processes. Our proprietary drug development approach selectively targets the activation of mTORC1 and offers an entirely new treatment approach for a broad range of chronic age-related diseases as well as several rare diseases that are linked to the genetic dysregulation of mTORC1 activation.

Navitor’s proprietary drug discovery platform is designed to develop first-in-class selective modulators of mTORC1 activation.

mTORC1 responds to and integrates the cell’s response to nutrient availability and growth factors and plays a key role in protein synthesis and cellular growth. As a critical regulatory pathway, mTORC1 is often dysregulated in multiple diseases across several important therapeutic areas. mTORC2 is critical for maintaining the sensitivity of cells to growth factors and for overall survival. While several approved drugs target the broad mTOR pathway for specific disease applications, the use of current mTOR-targeted drugs has been limited since they inhibit both mTORC1 and mTORC2, leading to undesirable side effects when used chronically. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity without inhibiting mTORC2 to address a wide range of chronic age-related diseases, including metabolic, neurodegenerative, autoimmune, chronic inflammatory, immunosenescence, and musculoskeletal diseases, as well as several rare genetic disorders.




Selective activation of mTORC1 offers a new and targeted approach to expand the therapeutic potential of a clinically validated pathway.

Disease Applications

Navitor's technology is applicable to developing novel product candidates addressing a wide range of diseases in which mTORC1 activation is dysregulated, including:

- **Obesity, type 2 diabetes, and other metabolic diseases** in which hyperactive mTORC1 activity is driven through the excess availability of nutrients and is thought to cause dysregulated cellular function and drive the disease process.
- **Alzheimer's, Parkinson's, and Huntington's diseases;** and other neurodegenerative diseases that involve abnormal protein folding, possibly due to excessive and unrestrained protein synthesis and reduced autophagy.
- **Psoriasis, rheumatoid arthritis, lupus, multiple sclerosis,** and other inflammatory and autoimmune diseases in which increased mTORC1 activity is thought to contribute to the activation of a specific subpopulation of T-cells that may create inflammation and tissue injury.
- **Immunosenescence,** where mTORC1 selective modulation of certain T-cell populations may improve vaccine efficacy in the aging population and enhance effectiveness of cancer immunotherapy.
- **Lymphangi leiomyomatosis (LAM), tuberous sclerosis,** and other rare diseases caused by a genetic defect in the mTORC1 signaling network, resulting in an uncontrolled hyperactivity of this complex.
- **Musculoskeletal diseases** including conditions that involve muscle loss, such as following immobilization and sarcopenia, in which protein synthesis and/or cell growth is deficient.

mTORC1 Activation is Central to Age-Related Disease Processes



Navitor is developing selective pharmacological modulators of mTORC1 activation.

By selectively targeting aberrant mTORC1 activation, Navitor is creating a new class of therapeutics designed to rebalance these signals to restore normal function and address the underlying biology of multiple diseases.

Navitor's approach is to selectively "turn up" or "turn down" these cellular signaling pathways to restore normal mTORC1 function. When the mTORC1 pathway becomes hyperactive in its signaling response to increased availability of nutrients or other factors, it is responsible for diseases such as obesity, type 2 diabetes, neurodegenerative diseases, and autoimmune and chronic inflammatory diseases, as well as rare genetic diseases.

Conversely, the reduced response of the mTORC1 pathway is commonly associated with deficits in skeletal muscle growth observed in musculoskeletal diseases such as age-related

sarcopenia, cachexia due to disease, and muscle atrophy due to immobilization, e.g. following orthopedic surgery.

World-class team and proprietary technology positioned for successful drug development.

Navitor is led by an experienced management and scientific team with a proven track record for discovering groundbreaking drugs and building successful drug development companies.

The company's founding intellectual property is based on seminal discoveries related to the mTORC1 activation pathway and related signaling mechanisms by its scientific founder, Dr. David Sabatini, at the Whitehead Institute for Biomedical Research.

The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Innovation – JJDC, SR One, and The Longevity Fund.

Navitor Product Development Approach

